ArticleJCO precision oncology2018
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
Open access · greenAbstract read
In one paragraph
Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 53 citations in OpenAlex.
- Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.NPJ precision oncology · 2026Article
- The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.JCO precision oncology · 2025Article
- Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boards.NPJ precision oncology · 2025Article
- Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Laser capture microdissection.Nature reviews. Methods primers · 2025Article
- Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.Cell reports. Medicine · 2024Article
- BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.Cancer gene therapy · 2024Article
- Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression.NPJ precision oncology · 2024Article
- Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer.NPJ precision oncology · 2024Article
- Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.Cancer science · 2024Review
- Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.Clinical proteomics · 2024Article
- Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.Cancer reports (Hoboken, N.J.) · 2024Article
- Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future.ESMO gastrointestinal oncology · 2024Review
- Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.Cell reports. Medicine · 2023Article
- Neratinib for HER2-positive breast cancer with an overlooked option.Molecular medicine (Cambridge, Mass.) · 2023Review
- Advances in the Management of Early-Stage Triple-Negative Breast Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Julia D Wulfkuhle, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Christina Yau, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Denise M Wolf, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Daniel J Vis, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Rosa I Gallagher, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Lamorna Brown-Swigart, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Gillian Hirst, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Emile E Voest, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Angela DeMichele, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Nola Hylton, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Fraser Symmans, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Douglas Yee, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Laura Esserman, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Donald Berry, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Minetta Liu, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
John W Park, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Lodewyk F A Wessels, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Laura Van't Veer, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
Emanuel F Petricoin, , and , George Mason University, Manassas, VA; , , , , , , , and , University of California, San Francisco, San Francisco, CA; , , and , Netherlands Cancer Institute, Amsterdam, the Netherlands; , University of Pennsylvania, Philadelphia, PA; , University of Texas MD Anderson Cancer Center, Houston; , Berry Consultants, Austin, TX; , University of Minnesota, Minneapolis; and , Mayo Clinic, Rochester, MN.
George Mason University · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and graduated in the HR-negative/HER2-positive signature. We hypothesized that neratinib response may be predicted by baseline HER2 epidermal growth factor receptor (EGFR) signaling activation/phosphorylation levels independent of total levels of HER2 or EGFR proteins. MATERIALS AND
methodsComplete experimental and response data were available for between 130 and 193 patients. In qualifying analyses, which used logistic regression and treatment interaction analysis, 18 protein/phosphoprotein, 10 mRNA, and 12 DNA biomarkers that related to
results
conclusionActivation of HER family phosphoproteins associates with response to neratinib, but only EGFR Y1173 and
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.